Ispravak
https://doi.org/10.11613/BM.2023.031201
Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience
Marija Gomerčić Palčić
; School of Medicine, University of Zagreb, Zagreb, Croatia
Hana Matijaca
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia
Ivan Kruljac
; Solmed Group, Department: Poliklinika Solmed, Zagreb, Croatia
Lucija Vusić
Vedran Hostić
; Department of Anesthesiology, Intensive Care Medicine and Pain Management, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Luka Vrbanić
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Pulmonology, Zagreb, Croatia
Fanika Mrsić
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia
Radovan Zrilić
; Polyclinic for Respiratory Diseases, Dom zdravlja Zagreb - Zapad, Zagreb, Croatia
Ivana Ćelap
; Department of Clinical Chemistry, Sestre milosrdnice University Hospital Center, Croatia
Petar Gaćina
; Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia
Puni tekst: engleski pdf 35 Kb
str. 359-360
preuzimanja: 124
citiraj
APA 6th Edition
Gomerčić Palčić, M., Matijaca, H., Kruljac, I., Vusić, L., Hostić, V., Vrbanić, L., ... Gaćina, P. (2023). Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience. Biochemia Medica, 33 (3), 359-360. https://doi.org/10.11613/BM.2023.031201
MLA 8th Edition
Gomerčić Palčić, Marija, et al. "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience." Biochemia Medica, vol. 33, br. 3, 2023, str. 359-360. https://doi.org/10.11613/BM.2023.031201. Citirano 25.11.2024.
Chicago 17th Edition
Gomerčić Palčić, Marija, Hana Matijaca, Ivan Kruljac, Lucija Vusić, Vedran Hostić, Luka Vrbanić, Fanika Mrsić, Radovan Zrilić, Ivana Ćelap i Petar Gaćina. "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience." Biochemia Medica 33, br. 3 (2023): 359-360. https://doi.org/10.11613/BM.2023.031201
Harvard
Gomerčić Palčić, M., et al. (2023). 'Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience', Biochemia Medica, 33(3), str. 359-360. https://doi.org/10.11613/BM.2023.031201
Vancouver
Gomerčić Palčić M, Matijaca H, Kruljac I, Vusić L, Hostić V, Vrbanić L i sur. Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience. Biochemia Medica [Internet]. 2023 [pristupljeno 25.11.2024.];33(3):359-360. https://doi.org/10.11613/BM.2023.031201
IEEE
M. Gomerčić Palčić, et al., "Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience", Biochemia Medica, vol.33, br. 3, str. 359-360, 2023. [Online]. https://doi.org/10.11613/BM.2023.031201
Preuzmi JATS datoteku
Sažetak
Ključne riječi
Hrčak ID:
308778
URI
https://hrcak.srce.hr/308778
Datum izdavanja:
15.10.2023.
Posjeta: 403
*